[1]ACSMedicinalChemistryLetters,2012,vol.3,#12,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,#12,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,#12,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,#12,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,#12,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.1091-1096
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.1091-1096
Title: Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.
Journal: Nature communications 20140101
Title: Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Journal: Cell cycle (Georgetown, Tex.) 20130701
Title: Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Journal: ACS medicinal chemistry letters 20121213
Title: Sharad K, et al. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6.
Title: Ding M, et al. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Clin Exp Pharmacol Physiol. 2015 May;42(5):458-64.
